This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrigan, P. R.
Right arrow Articles by Larder, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrigan, P. R.
Right arrow Articles by Larder, B. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 909-912, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.909-912.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates

P. Richard Harrigan{dagger} and Brendan A. Larder*

Virco UK Ltd., Cambridge, United Kingdom

Received 4 May 2001/ Returned for modification 2 August 2001/ Accepted 3 December 2001

The phenomenon of cross-resistance to antiretroviral agents used to treat human immunodeficiency virus type 1 infection is well known but so far has been only qualitatively described. Here, we quantitate the degree of cross-resistance among all commonly prescribed antiretroviral agents in almost 5,000 clinically derived recombinant isolates collected in the United States since January 2000.

* Corresponding author. Present address: Visible Genetics, 184 Cambridge Science Park, Cambridge CB4 0GA, United Kingdom. Phone: (44) 1223 728 800. Fax: (44) 1223 728 801. E-mail: brendan.larder{at}visgen.com.

{dagger} Present address: BC Centre for Excellence in HIV/AIDS, Vancouver, B.C., Canada V6Z 1Y6.

Antimicrobial Agents and Chemotherapy, March 2002, p. 909-912, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.909-912.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., de Bethune, M.-P. (2004). TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 4680-4686 [Abstract] [Full Text]  
  • Parkin, N. T., Hellmann, N. S., Whitcomb, J. M., Kiss, L., Chappey, C., Petropoulos, C. J. (2004). Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 437-443 [Abstract] [Full Text]  
  • Stevens, W., Kaye, S., Corrah, T. (2004). Antiretroviral therapy in Africa. BMJ 328: 280-282 [Full Text]  
  • Harrigan, P. R., Miller, M. D., McKenna, P., Brumme, Z. L., Larder, B. A. (2002). Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates. Antimicrob. Agents Chemother. 46: 1067-1072 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»